Physician profile
Michael L Beus
NPI 1770569543
$2,086.78
in general payments reported to CMS, 2019-2025
34 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $152 · 2021: $375 · 2022: $207 · 2023: $99.39 · 2024: $533 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.19 | 2021-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $285.66 | 2019-2025 | Arexvy, Shingrix |
| Pfizer INC. | $204.48 | 2019-2025 | |
| Astellas Pharma US INC | $107.77 | 2019-2024 | Veozah |
| Lilly USA, LLC | $101.04 | 2020-2025 | Mounjaro, Zepbound |
| Tris Pharma INC | $79.64 | 2024 | Dyanavel Xr |
| Inspire Medical Systems, INC. | $77.27 | 2024-2025 | Inspire |
| Amarin Pharma, INC. | $60.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $60.15 | 2019-2022 | |
| Novo Nordisk INC | $52.40 | 2019-2025 | Wegovy |
| Daiichi Sankyo INC. | $51.47 | 2021-2022 | |
| Amgen INC. | $50.96 | 2019-2025 | Evenity |
| Axsome Therapeutics, INC. | $49.50 | 2025 | Auvelity |
| Dexcom, INC. | $46.91 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $45.73 | 2024 | Gemtesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.72 | 2022-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.27 | 2025 | Caplyta |
| Allergan, INC. | $31.96 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.31 | 2020-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $25.54 | 2020-2022 | |
| Viatris Specialty LLC | $22.48 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $21.85 | 2023-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $19.56 | 2021 | |
| Abbott Laboratories | $16.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.75 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $14.62 | 2021 | |
| Exact Sciences Corporation | $14.22 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $14.15 | 2023 | Trintellix |
| Boston Scientific Corporation | $14.13 | 2019 | |
| Medtronic, INC. | $13.96 | 2022 | |
| Lundbeck LLC | $13.43 | 2023 | Rexulti |
| Lucid Diagnostics INC. | $13.26 | 2023 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Eisai INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Beus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.